BioMarin VOXZOGO Shows Long-Term Benefits for Achondroplasia in New Clinical Data at PES 2026

Key Takeaways

• VOXZOGO demonstrates sustained long-term benefits on arm span, bone health, and growth in children with achondroplasia after extended treatment
• The drug remains the only FDA-approved treatment for achondroplasia in children from birth, backed by over 10 years of clinical research
• BioMarin will also present hypochondroplasia study data ahead of pivotal Phase 3 results expected in first half 2026

---

BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) announced May 2, 2026, that new clinical data demonstrates VOXZOGO® (vosoritide) provides sustained long-term benefits for children with achondroplasia, including improvements in arm span, bone health, and overall growth patterns.

The San Rafael-based biotechnology company presented the findings at the Pediatric Endocrine Society’s 2026 annual meeting, reinforcing VOXZOGO’s position as the sole approved treatment for achondroplasia starting from birth.

Comprehensive Long-Term Safety and Efficacy Profile

The new data builds upon more than 10 years of clinical research demonstrating VOXZOGO’s ability to address multiple complications associated with achondroplasia, the most common form of dwarfism affecting approximately 1 in 15,000 to 1 in 40,000 births worldwide.

Achondroplasia results from mutations in the FGFR3 gene, leading to impaired bone and cartilage development. VOXZOGO works as a C-type natriuretic peptide analog that helps normalize the growth plate signaling pathway disrupted in this condition.

Expanding Treatment Applications

Beyond the achondroplasia data, BioMarin researchers presented additional findings from ongoing studies evaluating VOXZOGO for hypochondroplasia, a related but milder form of skeletal dysplasia. These results precede highly anticipated topline Phase 3 data for the hypochondroplasia indication, expected in the first half of 2026.

The hypochondroplasia program represents a significant market expansion opportunity, as this condition affects a broader patient population with similar underlying pathophysiology to achondroplasia.

Market Impact and Clinical Significance

VOXZOGO’s continued clinical success strengthens BioMarin’s leadership in rare disease therapeutics, particularly in skeletal disorders. The long-term data addressing arm span and bone health parameters provides crucial evidence for sustained treatment benefits beyond height velocity improvements previously demonstrated.

For families managing achondroplasia, these findings offer reassurance about VOXZOGO’s comprehensive impact on multiple aspects of the condition, potentially reducing long-term complications and improving quality of life outcomes for affected children.

---

Frequently Asked Questions

What does this new VOXZOGO data mean for patients with achondroplasia?

The data shows that long-term VOXZOGO treatment provides sustained benefits beyond height growth, including improvements in arm span proportions and bone health, suggesting comprehensive management of achondroplasia complications.

When will VOXZOGO be available for hypochondroplasia patients?

VOXZOGO is currently being studied for hypochondroplasia in Phase 3 trials, with topline results expected in the first half of 2026. Regulatory approval would follow if results are positive.

How does VOXZOGO compare to other achondroplasia treatments?

VOXZOGO is currently the only FDA-approved treatment specifically for achondroplasia in children from birth, with over 10 years of clinical research supporting its safety and efficacy profile.